Market research
7UM.F Ultimovacs ASA
F EUR Healthcare
Latest close
As of 01 Jul 2025
Test a moving-average rule with historical data.
Market facts
- Market cap
- 3M
- P/E ratio
- Not available
- Analyst target
- Not available
- Beta
- Not available
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- NO0010851603
- Market cap
- 3M
- P/E ratio
- Not available
- Analyst target
- Not available
- Beta
- Not available
About
About Ultimovacs ASA
As of March 3, 2025, Ultimovacs ASA acquired by Zelluna Immunotherapy AS. Ultimovacs ASA, a biotech company, develops immunotherapies against cancers in Norway. Its lead product candidate is UV1, a peptide-based therapeutic cancer vaccine that induces a specific T cell response against the pan-tumor antigen telomerase. Ultimovacs ASA was incorporated in 2011 and is headquartered in Oslo, Norway.
Research context
Ultimovacs ASA appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the 7UM.F discussion.
5 years, 7 months ago
Ultimovacs ASA is currently in a long term uptrend where the price is trading 9.3% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Ultimovacs ASA's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 3.1% to $-25M since the same quarter in the previous year.
Finally, its free cash flow grew by 1.1% to $-13M since the same quarter in the previous year.
Based on the above factors, Ultimovacs ASA gets an overall score of 4/5.